Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $85.86
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 18, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 30, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Jul 30, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 30, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Jul 29, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Jul 27, 26 | Wolfe Research | downgrade | Peer Perform | Underperform |
| May 28, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 28, 26 | Canaccord Genuity | maintain | Buy | Buy |
| May 13, 26 | UBS | upgrade | Neutral | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 24.27 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 20.70 | Oscillator | Neutral |
| Williams %R (14) | -95.53 | Oscillator | Buy |
| MACD (12, 26, 9) | -2.76 (Hist -2.59) | Oscillator | Strong Sell |
| Average Directional Index (14) | 22.58 (+DI 13.5 / -DI 46.9) | Trend | Sell |
| EMA 20 | 112.29 | MA | Strong Sell |
| SMA 20 | 114.69 | MA | Strong Sell |
| EMA 50 | 111.23 | MA | Strong Sell |
| SMA 50 | 115.21 | MA | Strong Sell |
| SMA 200 | 73.55 | MA | Strong Buy |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 16, 2026 | 2026-10-16 18:24:49 | View |
| 4 | Oct 5, 2026 | 2026-10-05 19:58:55 | View |
| 4 | Oct 5, 2026 | 2026-10-05 19:54:19 | View |
| 4 | Oct 5, 2026 | 2026-10-05 19:49:24 | View |
| 4 | Oct 5, 2026 | 2026-10-05 19:44:53 | View |
| 3 | Oct 5, 2026 | 2026-10-05 19:18:19 | View |
| 4 | Sep 28, 2026 | 2026-09-28 16:30:10 | View |
| 8-K | Sep 23, 2026 | 2026-09-23 08:15:05 | View |
| 4 | Sep 18, 2026 | 2026-09-18 19:53:38 | View |
| 4 | Sep 18, 2026 | 2026-09-18 19:47:51 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolo
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026.
CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) Director James Wilson sold 10,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $114.81, for a total value of $1,148,100.00. Following the completion of the sale, the director directly owned 1,054,543 shares of the
First Citizens Bank and Trust Co. trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 62.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,145 shares of the biotechnology company's stock after selling 6,771 shares during the period. First Citizens
ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | 0.02 | 0.36 | Beat 1383.3% | $256.1M |
| Apr 30, 2026 | -0.11 | -0.30 | Miss -172.3% | $164.9M |
| Feb 24, 2026 | 0.33 | 0.20 | Miss -39.4% | $202.1M |
| Nov 4, 2025 | 0.18 | 0.16 | Miss -11.1% | $207.6M |
| Jul 31, 2025 | 0.23 | 0.29 | Beat 26.1% | $194.4M |
| May 5, 2025 | 0.17 | 0.17 | Beat 0.0% | $157.2M |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Wilson James N | director | S-Sale | 6,654 @ $114.48 | $761.7K |
| Oct 15, 26 | Wilson James N | director | S-Sale | 3,046 @ $115.39 | $351.5K |
| Oct 15, 26 | Wilson James N | director | S-Sale | 300 @ $116.30 | $34.89K |
| Oct 2, 26 | Vieira Roberto Wandenkolk | officer: President, Oncology | M-Exempt | 8,333 @ $21.63 | $180.2K |
| Oct 2, 26 | Vieira Roberto Wandenkolk | officer: President, Oncology | M-Exempt | 8,333 @ $21.63 | $180.2K |
| Oct 2, 26 | Vieira Roberto Wandenkolk | officer: President, Oncology | S-Sale | 1,100 @ $114.52 | $126.0K |
| Oct 2, 26 | Vieira Roberto Wandenkolk | officer: President, Oncology | S-Sale | 2,086 @ $115.73 | $241.4K |
| Oct 2, 26 | Vieira Roberto Wandenkolk | officer: President, Oncology | S-Sale | 5,147 @ $116.59 | $600.1K |
TTM vs. 5-year historical average (annual ratios)
| Metric | CORT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 165.1x | 29.5x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 42.2x | EPS est. 2.04 | Discount |
| Price / Book | 12.8x | 6.1x | Elevated |
| Price / Sales | 11.2x | 6.2x | Elevated |
| EV / EBITDA | 318.9x | 28.5x | Elevated |
| Return on equity | 8.4% | — | Weak |
| Gross margin | 98.3% | 98.5% | In line |
| Debt / Equity | 0.01 | 0.00 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 40.57 | Safe zone |
Discounted cash flow model